Cory Randall Ellspermann - 18 Nov 2025 Form 4 Insider Report for Inmune Bio, Inc. (INMB)

Role: Interim CFO
Signature: /s/ Cory Randall Ellspermann
Issuer symbol: INMB
Transactions as of: 18 Nov 2025
Net transactions value: $0
Form type: 4
Filing time: 18 Nov 2025, 17:25:54 UTC
Previous filing: 18 Aug 2025
Next filing: 02 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ellspermann Cory Randall	Interim CFO	C/O INMUNE BIO INC., 225 NE MIZNER BLVD., SUITE 640, BOCA RATON	/s/ Cory Randall Ellspermann	18 Nov 2025	0002082083

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INMB	Stock Option (right to buy)	Disposed to Issuer	-75,000	-100%	0	18 Nov 2025	Common Stock	75,000	$3.91	Direct	F1, F2
transaction	INMB	Stock Option (right to buy)	Award	+75,000		75,000	18 Nov 2025	Common Stock	75,000	$1.50	Direct	F1, F2
transaction	INMB	Stock Option (right to buy)	Disposed to Issuer	-40,000	-100%	0	18 Nov 2025	Common Stock	40,000	$21.06	Direct	F1, F2
transaction	INMB	Stock Option (right to buy)	Award	+40,000		40,000	18 Nov 2025	Common Stock	40,000	$1.50	Direct	F1, F2
transaction	INMB	Stock Option (right to buy)	Disposed to Issuer	-30,000	-100%	0	18 Nov 2025	Common Stock	30,000	$7.92	Direct	F1, F2
transaction	INMB	Stock Option (right to buy)	Award	+30,000		30,000	18 Nov 2025	Common Stock	30,000	$1.50	Direct	F1, F2
transaction	INMB	Stock Option (right to buy)	Disposed to Issuer	-70,000	-100%	0	18 Nov 2025	Common Stock	70,000	$5.05	Direct	F1, F2
transaction	INMB	Stock Option (right to buy)	Award	+70,000		70,000	18 Nov 2025	Common Stock	70,000	$1.50	Direct	F1, F2
transaction	INMB	Stock Option (right to buy)	Disposed to Issuer	-30,000	-100%	0	18 Nov 2025	Common Stock	30,000	$9.92	Direct	F1, F2
transaction	INMB	Stock Option (right to buy)	Award	+30,000		30,000	18 Nov 2025	Common Stock	30,000	$1.50	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.
F2	This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Content

Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.